Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia (Q33949752)

30 July 2017

title

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia (English)

1 reference

30 July 2017

1 reference

1 reference

acute myeloid leukemia

1 reference

2

Hagop Kantarjian

1 reference

30 July 2017

12

Alessandra Ferrajoli

1 reference

30 July 2017

20

Stefan Faderl

1 reference

30 July 2017

17

Zeev Estrov

1 reference

30 July 2017

11

Jorge Cortes

1 reference

30 July 2017

9

Tapan Kadia

1 reference

30 July 2017

3

Farhad Ravandi

1 reference

30 July 2017

7

Elias Jabbour

1 reference

30 July 2017

8

Gautam Borthakur

1 reference

30 July 2017

Guillermo Garcia-Manero

series ordinal

6

object named as

Guillermo Garcia-Manero

1 reference

30 July 2017

10

Marina Konopleva

1 reference

30 July 2017

16

Michael Andreeff

1 reference

30 July 2017

15

Naveen Pemmaraju

1 reference

30 July 2017

14

Naval Daver

1 reference

30 July 2017

19

Mark Brandt

1 reference

30 July 2017

4

Xuelin Huang

1 reference

30 July 2017

1

Aziz Nazha

1 reference

30 July 2017

5

Sangbum Choi

1 reference

30 July 2017

13

Steve Kornblau

1 reference

30 July 2017

Min Du

18

1 reference

30 July 2017

publication date

9 September 2013

1 reference

American Journal of Hematology

30 July 2017

published in

1 reference

30 July 2017

volume

88

1 reference

30 July 2017

issue

11

1 reference

30 July 2017

page(s)

961-966

1 reference

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Anthracycline dose intensification in acute myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Clofarabine combinations as acute myeloid leukemia salvage therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Clofarabine: past, present, and future

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Age and acute myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Biochemical modulation of cytarabine triphosphate by clofarabine.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr

5 July 2018

1 reference

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

21 January 2018

1 reference

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.

21 January 2018

1 reference

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

21 January 2018

1 reference

Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro

21 January 2018

1 reference

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

21 January 2018

1 reference

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110914

29 October 2018

Acute myeloid leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23877926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23877926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23877926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/AJH.23544

1 reference

30 July 2017

1 reference

30 July 2017

1 reference